VolitionRX Limited (NYSEAMERICAN:VNRX – Get Free Report) was the target of a large decline in short interest during the month of April. As of April 30th, there was short interest totaling 269,068 shares, a decline of 96.2% from the April 15th total of 7,087,765 shares. Approximately 3.6% of the shares of the stock are sold short. Based on an average trading volume of 193,588 shares, the short-interest ratio is presently 1.4 days.
Wall Street Analysts Forecast Growth
VNRX has been the topic of a number of research reports. HC Wainwright reduced their price objective on VolitionRX from $30.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. Citigroup lowered VolitionRX to a “hold” rating in a research report on Monday, April 20th. Finally, D. Boral Capital reiterated a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.67.
View Our Latest Stock Report on VNRX
VolitionRX Stock Down 8.9%
Institutional Investors Weigh In On VolitionRX
Several institutional investors and hedge funds have recently made changes to their positions in VNRX. Virtu Financial LLC raised its stake in VolitionRX by 166.6% during the 4th quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock worth $28,000 after buying an additional 67,848 shares during the period. Squarepoint Ops LLC acquired a new position in VolitionRX during the 4th quarter worth approximately $34,000. Jane Street Group LLC acquired a new position in VolitionRX during the 4th quarter worth approximately $28,000. Geode Capital Management LLC raised its stake in VolitionRX by 9.8% during the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after buying an additional 85,816 shares during the period. Finally, Armistice Capital LLC raised its stake in VolitionRX by 10.4% during the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after buying an additional 887,351 shares during the period. Institutional investors own 8.09% of the company’s stock.
VolitionRX Company Profile
VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.
The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.
Read More
- Five stocks we like better than VolitionRX
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.
